BridgeBio’s Post

📢 Breaking News: A Huge Step Forward for ATTR-CM #amyloidosis patients. 👏🏾👏🏾👏🏾👏🏾Thank you to the clinical team and especially the patients who volunteered for the clinical trials. Your work creates many more years with our loved ones. ❤️🩹 Johnny Boatman has been fighting bravely for 79 days in the hospital, awaiting a life-saving heart transplant. His journey shines a light on the critical need for advancements in treatments for conditions like Amyloidosis, specifically ATTR-CM (transthyretin amyloid cardiomyopathy). Today, we celebrate a game-changing milestone: the FDA approval of BridgeBio's Attruby™ (acoramidis), a groundbreaking therapy for ATTR-CM. Backed by the ATTRibute-CM Phase 3 study, Attruby has been proven to significantly reduce cardiovascular death and hospitalization, while improving patients' quality of life. As Muriel Finkel, President of the Amyloidosis Support Groups Inc., states: "Access to this new therapy means more hope and more opportunities to improve the lives of patients with amyloidosis." Attruby is the first and only near-complete (≥90%) stabilizer of TTR, preserving its native function as a transport protein and delivering real impact on cardiovascular outcomes. This treatment could mean fewer hospital stays, fewer transplants, and more moments of life lived to the fullest for patients like Johnny. 🎉 Let’s celebrate this monumental step toward giving hope and better futures to those battling ATTR-CM. Together, we can advocate for innovation, support, and access to life-saving treatments. #AmyloidosisAwareness #ATTRCM #AnyoneWithAHeart

22-Nov-2024: This is a very good day for patients with #ATTR-CM in the US: a new oral treatment has been approved by the US FDA that targets the disease at its source. BridgeBio, Bayer and Alexion Pharmaceuticals, Inc. are working diligently to make this new treatment available in other countries. #cardiomyopathy #amyloidosis #patientsfirst   ATTR-CM (transthyretin amyloid cardiomyopathy) is a form of #heartfailure that inexorably progresses, leading to repeat hospitalizations and death. You can think of it as being an equivalent of Alzheimer’s disease for the heart (with a buildup of toxic protein components in the cardiac tissue). Although shown in some studies to account for up to ~15% of heart failure with preserved ejection fraction (#HFpEF), ATTR-CM is vastly under-recognized. Early diagnosis and prompt treatment initiation with a targeted therapy are essential however to improve outcomes.   Shoutout to the Cardiology Societies (AHA/ACC/HFSA, ESC and others) and Patient Advocacy Organizations around the world for their outreach to stakeholders (affected families, healthcare professionals, cardiologists and the broader medical community) and their efforts to raise awareness and educate on this disease that is hiding in plain sight.   Link to 2023 ACC Expert Decision Consensus Pathway for the care of patients with ATTR-CM: https://lnkd.in/gJPrxHJB

Congratulations to the BridgeBio team Neil Kumar🎉! FDA has announced the approval of Attruby™ (acoramidis), a near complete TTR stabilizer (≥90%) for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalization. ATTR-CM is a rare and progressive disease where a protein called transthyretin (TTR) misfolds and forms harmful amyloid deposits in the heart. Over time, these deposits can lead to heart failure, making it difficult for the heart to pump blood properly. Although treatments for ATTR-CM have been limited, the approval of Attruby offers new hope for patients affected by this debilitating disease. The approval of acoramidis comes less than 10 months after BridgeBio Pharma announced the FDA’s acceptance of their New Drug Application (NDA) in February 2024. Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefits on cardiovascular outcomes, offering a new treatment option for those affected by this serious disease. #geneticdiseases #cardiomyopathy #rarediseases #clinicaltrial #amyloidosis #biomarker

Dial in to review published evidence around the OmniaSecure™ defibrillation lead. Join an expert panel as they discuss the LEADR global pivotal trial results, benchtop assessment on 10-year projected lead durability, and other related insights around published OmniaSecure evidence. https://bit.ly/3YUUhin CAUTION: investigational device. Limited by federal (U.S.) law to investigational use. Not approved by FDA and not for sale in the U.S. nor anywhere worldwide.

Dial in to review published evidence around the OmniaSecure™ defibrillation lead. Join an expert panel as they discuss the LEADR global pivotal trial results, benchtop assessment on 10-year projected lead durability, and other related insights around published OmniaSecure evidence. https://bit.ly/48STPpt CAUTION: investigational device. Limited by federal (U.S.) law to investigational use. Not approved by FDA and not for sale in the U.S. nor anywhere worldwide.

A significant accomplishment in the improvement of the diagnostic accuracy, and timeliness of sepsis testing results; in less than 8 minutes; and with traditional methods for diagnosis of several days. As remarkable as the Abionic technology is, the true break-out would be a hand-held testing instrument and sample processing cartridge for a blood droplet, and readily available at all point-of-care locations, and this being crucial to minimize the diagnosis timeline. Sepsis is the body's exaggerated response to infection, and can cause widespread inflammation and organ failure. It is one of the leading causes of death in the United States, on par with cancer and heart disease. It is a disease that is difficult to detect and research shows that sepsis can kill an affected person in as little as 12 hours. Given such a limited time for diagnosis and treatment, that identifies the pathogens and their antibiotic sensitivity and resistance; the sooner the person is aware of their peril with sepsis and then seeks medical attention, the better. The acronym T.I.M.E. can help you recognize the signs and symptoms of sepsis: T: Temperature — higher or lower than normal I: Infection — signs and symptoms of an infection M: Mental decline — sleepy, difficult to rouse, confused E: Extremely ill — severe pain, discomfort, shortness of breath

📕 Article details some of the current clinical trials being conducted for possible new treatments: https://lnkd.in/gYXpZRc8 #Lung #Clinicaltrials #IPF #Prevalence #Clinicalendpoints #Pulmonary #Healthcare

An Agent of change for a previously unmet clinical need in the United States. Patients with recurrent in-stent restenosis will now have access to a therapy that is proven to be safe and superior to balloon angioplasty alone. It is known that MACE rates rise with each subsequent stent layer used to treat in-stent restenosis; having another means to deliver an anti-proliferative drug without leaving behind more metal will be truly life changing for an untold amount of people. As even more data comes out, it will be exciting to see the full range of utility DCBs will have in the coronary space. Truly the start of a new chapter in interventional cardiology!

Exciting news for us in the USA! Key takeaways: - current use: in stent restenosis - minimum inflation time: 30 seconds - drug: TransPax (derivative of Paclitaxel) - DAPT: still recommended for 3 months Would love to hear your thoughts! And any feedback from users in Europe & other countries who have used it. #newtechnology #bostonscientific #dcb #instentrestenosis #interventionalcardiology

Idiopathic pulmonary fibrosis (#IPF) prevalence is on the rise globally. There is currently no cure for IPF and only 2 FDA approved treatments. Our article details some of the current clinical trials being conducted for possible new treatments: https://lnkd.in/gYXpZRc8 #LungHealth #PulmonaryFibrosis #Respiratory #IdiopathicPulmonaryFibrosis #MERITCRO #YourClinicalEndpointExpert